Crescita Therapeutics Inc (CTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Crescita Therapeutics Inc (CTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8166
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Crescita Therapeutics Inc (Crescita Therapeutics) is a commercial dermatology company that offers prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. The company’s products comprise Pliaglis, Alyria, Laboratoire Dr Renaud, Pro-Derm, Premiology and ISDIN. Its Pliaglis is a local anesthetic cream for superficial dermatological and cosmetic procedures. Crescita Therapeutics develops Mical used in therapeutic areas of psoriasis and dermatological skin treatment. The company develops products using drug delivery platforms which include multiplexed molecular penetration enhancers and DuraPeel. It markets products in the US, Canada and Mexico. Crescita Therapeutics is headquartered in Laval, Ontario, Canada.

Crescita Therapeutics Inc (CTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 11
Licensing Agreements 12
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 12
Crescita Therapeutics Enters into Licesning Agreement with US Contract Research Company 13
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 14
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 15
Equity Offering 16
Crescita Therapeutics Raises USD3.7 Million in Rights Offering of Shares 16
Debt Offering 17
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 17
Asset Transactions 18
Crescita Therapeutics Divests Manufacturing Facility in Germany 18
Acquisition 19
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 19
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 20
Crescita Therapeutics Inc – Key Competitors 21
Crescita Therapeutics Inc – Key Employees 22
Crescita Therapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 10, 2018: Crescita Therapeutics reports 2018 second quarter results 24
May 09, 2018: Crescita Therapeutics Reports 2018 First Quarter Results 27
Mar 28, 2018: Crescita Therapeutics Reports 2017 Fourth Quarter and Year End Results 29
Nov 10, 2017: Crescita Therapeutics Announces 2017 Third Quarter Results and Appoints New CFO 31
Aug 14, 2017: Crescita Therapeutics Announces Profitable 2017 Second Quarter Results 33
May 15, 2017: Crescita Therapeutics Announces 2017 First Quarter Results 35
Mar 30, 2017: Crescita Therapeutics Announces 2016 Fourth Quarter and Year-End Results 37
Corporate Communications 39
Apr 03, 2018: Crescita Therapeutics Announces the Appointment of Serge Verreault as President & CEO 39
Apr 12, 2017: Crescita Therapeutics Announces the Appointment of a New President 40
Feb 10, 2017: Crescita Therapeutics Announces Management and Board Changes 41
Product News 42
Jan 26, 2017: Crescita Therapeutics Announces Launch of ISDIN Product Line at Brunet Pharmacy 42
Other Significant Developments 43
Oct 15, 2018: Crescita’s patented delivery technologies demonstrate enhanced skin permeation of cannabidiol 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Crescita Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 11
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 12
Crescita Therapeutics Enters into Licesning Agreement with US Contract Research Company 13
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 14
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 15
Crescita Therapeutics Raises USD3.7 Million in Rights Offering of Shares 16
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 17
Crescita Therapeutics Divests Manufacturing Facility in Germany 18
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 19
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 20
Crescita Therapeutics Inc, Key Competitors 21
Crescita Therapeutics Inc, Key Employees 22
Crescita Therapeutics Inc, Subsidiaries 23

List of Figures
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Crescita Therapeutics Inc (CTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bullfrog Power Inc.-エネルギー分野:企業M&A・提携分析
    Summary Bullfrog Power Inc. (Bullfrog Power) is a provider of green energy. The company offers renewable energy solutions that help businesses and houses in reducing their environmental impact. Bullfrog's product portfolio includes green electricity, green fuel and green natural gas. The company, th …
  • Allied Digital Services Limited (ADSL):企業の財務・戦略的SWOT分析
    Allied Digital Services Limited (ADSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Pulmagen Therapeutics LLP:製薬・医療:M&Aディール及び事業提携情報
    Summary Pulmagen Therapeutics LLP (Pulmagen) formerly Argenta Discovery Ltd, is a development stage pharmaceutical company, which develops oral and inhaled medicines for chronic respiratory diseases. The company’s product pipeline includes oral CRTh2 antagonists, inhaled bronchodilators, inhaled per …
  • Itochu Techno-Solutions Corp (4739):企業の財務・戦略的SWOT分析
    Itochu Techno-Solutions Corp (4739) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Hansol Logistics Co., Ltd. (009180):企業の財務・戦略的SWOT分析
    Hansol Logistics Co., Ltd. (009180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Bechtel Corporation-エネルギー分野:企業M&A・提携分析
    Summary Bechtel Corporation (Bechtel) is a provider of engineering, construction and project management services. It provides a diverse portfolio of services to energy, transportation, communications, mining, oil and gas, chemicals, water, nuclear and government customers across the world. Its major …
  • Birla Corporation Ltd:企業の戦略・SWOT・財務情報
    Birla Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Birla Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Censa Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Censa Pharmaceuticals Inc (Censa Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for the treatment of rare central nervous system (CNS) disorders. The company provides product pipeline such as therapies for the treatment of extremely rare disorders …
  • Singapore Telecommunications Ltd:企業の戦略・SWOT・財務分析
    Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report Summary Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Kitoku Shinryo Co., Ltd.:企業の戦略・SWOT・財務情報
    Kitoku Shinryo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kitoku Shinryo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bukwang Pharm Co Ltd (003000):製薬・医療:M&Aディール及び事業提携情報
    Summary Bukwang Pharm Co Ltd (Bukwang Pharmaceutical) is a pharmaceutical company that develops new drugs and pharmaceutical products. The company’s products portfolio includes dexid, thioctacid, levovir, legalon, Orfil, azeptin, lonasen, ixel, and asima, among others. Its pipeline products comprise …
  • Central Bank of Egypt:企業の戦略的SWOT分析
    Central Bank of Egypt - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Intermountain Rural Electric Association:企業の戦略的SWOT分析
    Intermountain Rural Electric Association - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Jura Energy Corp (JEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Jura Energy Corp (Jura Energy), formerly Proprietary Industries Inc., is an independent upstream company. It explores, develops and produces crude oil and natural gas from its assets in Pakistan. The company undertakes upstream operations in Pakistan through its wholly-owned subsidiaries, na …
  • Quantum Fuel Systems LLC:企業の戦略的SWOT分析
    Quantum Fuel Systems LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Medikit Co Ltd (7749):企業の財務・戦略的SWOT分析
    Summary Medikit Co Ltd (Medikit) is a medical equipment provider that offers vascular devices. The company offers IV catheter, hemodialysis and intervention products. Its products include supercath Z3V, supercath 5 safety IV catheter, supercath AZ, supercath CLS, i-works, seiha, parent plus, parent …
  • Centrais Eletricas do Para SA (CELP5):電力:M&Aディール及び事業提携情報
    Summary Centrais Eletricas do Para SA (CELPA), a subsidiary of Equatorial Energia SA is an electric utility that supplies and distributes power and electricity. The utility offers services such as electric metering, online bill payment, surge protection, outage reporting, energy saving tips, rebates …
  • GUD Holdings Limited (GUD):企業の財務・戦略的SWOT分析
    GUD Holdings Limited (GUD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Al Rajhi Banking & Investment Corp (1120):企業の財務・戦略的SWOT分析
    Al Rajhi Banking & Investment Corp (1120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Shri Lakshmi Cotsyn Ltd.:企業の戦略・SWOT・財務分析
    Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆